Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.36
EW's Cash-to-Debt is ranked lower than
63% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. EW: 1.36 )
Ranked among companies with meaningful Cash-to-Debt only.
EW' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.11 Max: 9.48
Current: 1.36
0
9.48
Equity-to-Asset 0.58
EW's Equity-to-Asset is ranked lower than
62% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. EW: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
EW' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.6 Max: 0.85
Current: 0.58
0.37
0.85
Debt-to-Equity 0.33
EW's Debt-to-Equity is ranked lower than
58% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. EW: 0.33 )
Ranked among companies with meaningful Debt-to-Equity only.
EW' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.31 Max: 1.29
Current: 0.33
0.03
1.29
Debt-to-EBITDA 1.03
EW's Debt-to-EBITDA is ranked higher than
65% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. EW: 1.03 )
Ranked among companies with meaningful Debt-to-EBITDA only.
EW' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13  Med: 0.63 Max: 1.03
Current: 1.03
0.13
1.03
Interest Coverage 176.17
EW's Interest Coverage is ranked higher than
55% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. EW: 176.17 )
Ranked among companies with meaningful Interest Coverage only.
EW' s Interest Coverage Range Over the Past 10 Years
Min: 18.97  Med: 63.1 Max: 176.17
Current: 176.17
18.97
176.17
Piotroski F-Score: 7
Altman Z-Score: 8.04
Beneish M-Score: -2.50
WACC vs ROIC
6.13%
31.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 28.70
EW's Operating Margin % is ranked higher than
95% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. EW: 28.70 )
Ranked among companies with meaningful Operating Margin % only.
EW' s Operating Margin % Range Over the Past 10 Years
Min: 13.99  Med: 22.1 Max: 53.09
Current: 28.7
13.99
53.09
Net Margin % 22.47
EW's Net Margin % is ranked higher than
93% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. EW: 22.47 )
Ranked among companies with meaningful Net Margin % only.
EW' s Net Margin % Range Over the Past 10 Years
Min: 10.36  Med: 16.35 Max: 34.92
Current: 22.47
10.36
34.92
ROE % 26.31
EW's ROE % is ranked higher than
94% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. EW: 26.31 )
Ranked among companies with meaningful ROE % only.
EW' s ROE % Range Over the Past 10 Years
Min: 14.26  Med: 20.89 Max: 43.42
Current: 26.31
14.26
43.42
ROA % 15.35
EW's ROA % is ranked higher than
94% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. EW: 15.35 )
Ranked among companies with meaningful ROA % only.
EW' s ROA % Range Over the Past 10 Years
Min: 8.72  Med: 13.18 Max: 26.03
Current: 15.35
8.72
26.03
ROC (Joel Greenblatt) % 85.47
EW's ROC (Joel Greenblatt) % is ranked higher than
91% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. EW: 85.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EW' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.35  Med: 57.83 Max: 138.73
Current: 85.47
41.35
138.73
3-Year Revenue Growth Rate 14.80
EW's 3-Year Revenue Growth Rate is ranked higher than
77% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. EW: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EW' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 11.5 Max: 15.1
Current: 14.8
-9.7
15.1
3-Year EBITDA Growth Rate 14.00
EW's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. EW: 14.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EW' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 16 Max: 57.8
Current: 14
-20.2
57.8
3-Year EPS without NRI Growth Rate 15.10
EW's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. EW: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EW' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.85 Max: 288.2
Current: 15.1
0
288.2
GuruFocus has detected 3 Warning Signs with Edwards Lifesciences Corp EW.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EW's 30-Y Financials

Financials (Next Earnings Date: 2018-02-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

EW Guru Trades in Q4 2016

Ron Baron 40,284 sh (+274.32%)
Lee Ainslie 38,440 sh (+42.90%)
Steven Cohen 476,400 sh (+40.99%)
Eaton Vance Worldwide Health Sciences Fund 269,163 sh (+26.22%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Frank Sands 8,327,338 sh (-7.84%)
Pioneer Investments 1,512,359 sh (-14.19%)
Jim Simons 865,200 sh (-41.40%)
» More
Q1 2017

EW Guru Trades in Q1 2017

Paul Tudor Jones 208,491 sh (New)
Ray Dalio 45,415 sh (New)
David Rolfe 1,137,072 sh (New)
Jim Simons 926,300 sh (+7.06%)
PRIMECAP Management 560,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 269,163 sh (unchged)
Louis Moore Bacon Sold Out
Ron Baron 39,576 sh (-1.76%)
Frank Sands 8,007,203 sh (-3.84%)
Lee Ainslie 30,890 sh (-19.64%)
Pioneer Investments 647,157 sh (-57.21%)
Steven Cohen 113,075 sh (-76.26%)
» More
Q2 2017

EW Guru Trades in Q2 2017

George Soros 4,600 sh (New)
Steven Cohen 446,400 sh (+294.78%)
Lee Ainslie 33,680 sh (+9.03%)
Pioneer Investments 684,809 sh (+5.82%)
PRIMECAP Management 560,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 269,163 sh (unchged)
Frank Sands 7,633,175 sh (-4.67%)
Ron Baron 37,266 sh (-5.84%)
Jim Simons 852,900 sh (-7.92%)
Ray Dalio 40,694 sh (-10.40%)
David Rolfe 861,348 sh (-24.25%)
Paul Tudor Jones 9,581 sh (-95.40%)
» More
Q3 2017

EW Guru Trades in Q3 2017

Joel Greenblatt 7,936 sh (New)
Ray Dalio 119,747 sh (+194.26%)
Paul Tudor Jones 26,427 sh (+175.83%)
Jim Simons 2,200,739 sh (+158.03%)
David Rolfe 1,343,047 sh (+55.92%)
Lee Ainslie 45,890 sh (+36.25%)
Steven Cohen 474,495 sh (+6.29%)
Pioneer Investments 690,472 sh (+0.83%)
Ron Baron 37,386 sh (+0.32%)
George Soros Sold Out
Frank Sands 7,236,435 sh (-5.20%)
PRIMECAP Management 525,400 sh (-6.18%)
Eaton Vance Worldwide Health Sciences Fund 174,360 sh (-35.22%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-09-30 Add 0.32%$108.87 - $119.58 $ 108.81-5%37,386
Joel Greenblatt 2017-09-30 New Buy0.01%$108.87 - $119.58 $ 108.81-5%7,936
George Soros 2017-09-30 Sold Out 0.01%$108.87 - $119.58 $ 108.81-5%0
Ron Baron 2017-06-30 Reduce -5.84%$93.09 - $120.15 $ 108.81-0%37,266
George Soros 2017-06-30 New Buy0.01%$93.09 - $120.15 $ 108.81-0%4,600
Ron Baron 2017-03-31 Reduce -1.76%$89.49 - $99.14 $ 108.8116%39,576
Ron Baron 2016-12-31 Add 274.32%0.01%$81.47 - $121.36 $ 108.8112%40,284
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NAS:ALGN, NYSE:ZBH, LSE:SN., XSWX:SOON, NYSE:TFX, NYSE:VAR, NAS:ABMD, ASX:COH, OCSE:WDH, XPAR:DIM, SZSE:300003, NZSE:FPH, LSE:CTEC, NAS:MASI, OCSE:GN, NYSE:BSX, OSTO:EKTA B, OCSE:AMBU B, NAS:IART, NAS:LIVN » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Headquarter Location:USA
Edwards Lifesciences Corp is a part of the healthcare sector. The company specializes in the treatment of structural heart disease. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of heart disease. Its key products include tissue heart valves, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Guru Investment Theses on Edwards Lifesciences Corp

David Rolfe Comments on Edwards Lifesciences - Apr 14, 2017

We established a new position in Edwards Lifesciences (NYSE:EW) in the first quarter. Edwards is a pioneer in heart valve surgery, with nearly 90% of its revenues tied to heart valve replacement, by virtue of its best-in-class portfolio of intellectual property, backed by a relatively lengthy history of clinical data and successful outcomes. Heart disease is the world’s leading killer, and the incidence of heart disease grows with age, meaning that the aging of populations across the developed world is directly leading to a rise in the occurrence of heart problems. Over half of the Company’s business is tied to the rapidly-growing TAVR, or Transcatheter Aortic Valve Replacement, category. TAVR—as opposed to SAVR, which is Surgical Aortic Valve Replacement, which is generally a type of open-heart surgery—is a fairly recent technological advancement, with the first human procedure occurring in 2002; the first market approval in Europe in 2007; and US approval in 2011. We view TAVR, which replaces a heart valve using a small incision, usually in a patient’s leg, as clearly superior to traditional open-heart surgery, with similar clinical results at a comparable price, but without the need to crack open a patient’s chest. As the market for TAVR has developed, it was first approved for patients for whom traditional surgery was too risky to be a viable option, followed by patients for whom surgery was considered a high risk. 2016 saw a surge in procedures as TAVR was approved for patients for whom surgery is an intermediate risk, and clinical trials are underway to seek approval for low-risk patients, as well.

EW is the clear market leader in the TAVR segment of the market, and we expect its TAVR solutions to continue to gain significant share industry-wide over time as the procedure spreads into the low-risk patient population, especially as regulatory issues constraining the growth of the procedure ease over time, and as the industry invests in patient and physician education to expand the overall valve-replacement population, well beyond prior expectations. In addition, there are a significant amount of underserved populations among patients not yet showing symptoms and patients who might not have considered treatment previously, when the only option was to have their chests cracked open. We believe, over time, that TAVR’s superior, much less invasive treatment option could lead to earlier screening of asymptomatic patients, as well as to patients proactively inquiring about therapy.

On the valuation front, the stock looks attractive in relation to peers and the broader market, having pulled back almost a third from its highs, down to the middle of its historical valuation range, after the past few quarters of earnings results slightly underperformed versus very high expectations. Specifically, there was a temporary issue with France running out of money in its budget for TAVR reimbursement, as the budget had not anticipated the tremendous growth in TAVR procedures for intermediate-risk patients. We view this as a non-issue, longer-term. Further, the sequential growth rate for TAVR revenues slowed in the second half of 2016, despite a continuation of extremely healthy year-over-year growth, which registered nearly 30% globally and nearly 40% in the US in the fourth quarter, for example. We view this as very attractive growth and understand that there will be fits and starts in sequential growth rates around product approval cycles. Longer-term, we view Edwards as an attractive growth opportunity, as aging populations lead to increasing heart disease, and as TAVR takes share within the valve-replacement market. We see opportunities for growth within the established patient population, in addition to current estimates of the patient population that we think are significantly understated, meaning that the market’s long-term growth expectations are also understated. We believe the under-appreciated growth opportunities, the secular shift towards less invasive procedures, and the reasonable valuation makes EW an attractive long-term holding.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners first-quarter 2017 shareholder letter.

Check out David Rolfe latest stock trades

Baron Opportunity Fund Comments on Edwards - Feb 21, 2017

Edwards (NYSE:EW) is the world’s leading manufacturer of tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. Edwards has leveraged the knowledge and experience from its surgical tissue heart valve business to develop transcatheter heart valve replacement technologies, designed to treat heart valve disease using catheter-based approaches as opposed to open surgery. Transcatheter aortic valve replacement (TAVR) is an innovative procedure in which a valve is inserted through a catheter and implanted within the diseased aortic valve. The procedure is significantly less invasive than surgery, takes about 90 minutes and recovery can be as short as a few days. TAVR is transforming the market because it provides a new, less invasive treatment option for patients ineligible for surgery or at high surgical risk. Edwards believes there are about 650,000 aortic stenosis patients addressable with TAVR–over twice their prior view of the addressable market–only a fraction of which are being treated with TAVR today. Edwards is also investing in transcatheter valve technologies to treat patients with mitral and tricuspid diseases–which present large, untapped addressable markets (2.5 million for mitral and 1.5 million for tricuspid)–and have the potential to open up significant new growth opportunities for the company.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Edwards Lifesciences Corp

Edwards SAPIEN 3 Transcatheter Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate Risk Patients
Edwards Lifesciences To Host Earnings Conference Call On October 24, 2017
Edwards Announces Key Events For PCR London Valves 2017
Edwards Lifesciences To Present At The 12th Annual Wells Fargo Healthcare Conference
Edwards Lifesciences To Present At 37th Annual Canaccord Genuity Growth Conference
Edwards Lifesciences To Host Earnings Conference Call On July 26, 2017
Quality Stocks Gurus Are Buying All-In-One Screener identifies great companies
According to GuruFocus’ All-In-One Screener, the following stocks have high business predictability ratings and positive total returns since the beginning of the year. Read more...
Edwards Lifesciences To Present At Goldman Sachs 38th Annual Global Healthcare Conference
Edwards SAPIEN 3 Valve Receives FDA Approval For Aortic, Mitral Valve-In-Valve Procedures
David Rolfe's Quest for 'Huge Winners' The guru behind the RiverPark/Wedgewood Fund counts on occasional big gains to maintain benchmark-beating returns
David Rolfe (Trades, Portfolio) of Wedgewood Partners Inc. is one of the GuruFocus gurus who’s beaten the Standard & Poor's 500 on most cumulative returns over the past two decades. Read more...

Ratios

vs
industry
vs
history
PE Ratio 31.72
EW's PE Ratio is ranked lower than
56% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. EW: 31.72 )
Ranked among companies with meaningful PE Ratio only.
EW' s PE Ratio Range Over the Past 10 Years
Min: 11.18  Med: 30.35 Max: 50.58
Current: 31.72
11.18
50.58
Forward PE Ratio 25.51
EW's Forward PE Ratio is ranked lower than
58% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. EW: 25.51 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.72
EW's PE Ratio without NRI is ranked lower than
57% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. EW: 31.72 )
Ranked among companies with meaningful PE Ratio without NRI only.
EW' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.16  Med: 30.27 Max: 49.62
Current: 31.72
11.16
49.62
Price-to-Owner-Earnings 36.95
EW's Price-to-Owner-Earnings is ranked lower than
58% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 37.10 vs. EW: 36.95 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EW' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.88  Med: 36.49 Max: 572.5
Current: 36.95
7.88
572.5
PB Ratio 7.28
EW's PB Ratio is ranked lower than
84% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. EW: 7.28 )
Ranked among companies with meaningful PB Ratio only.
EW' s PB Ratio Range Over the Past 10 Years
Min: 2.9  Med: 5.9 Max: 10.16
Current: 7.28
2.9
10.16
PS Ratio 7.11
EW's PS Ratio is ranked lower than
77% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. EW: 7.11 )
Ranked among companies with meaningful PS Ratio only.
EW' s PS Ratio Range Over the Past 10 Years
Min: 2.31  Med: 5.02 Max: 9.42
Current: 7.11
2.31
9.42
Price-to-Free-Cash-Flow 36.19
EW's Price-to-Free-Cash-Flow is ranked lower than
66% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. EW: 36.19 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EW' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.82  Med: 39.21 Max: 517.1
Current: 36.19
7.82
517.1
Price-to-Operating-Cash-Flow 28.12
EW's Price-to-Operating-Cash-Flow is ranked lower than
69% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. EW: 28.12 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EW' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.33  Med: 28.15 Max: 48.87
Current: 28.12
7.33
48.87
EV-to-EBIT 24.56
EW's EV-to-EBIT is ranked lower than
56% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. EW: 24.56 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 22.1 Max: 39.7
Current: 24.56
6.8
39.7
EV-to-EBITDA 22.60
EW's EV-to-EBITDA is ranked lower than
64% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. EW: 22.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 17.45 Max: 33.5
Current: 22.6
6.4
33.5
EV-to-Revenue 6.84
EW's EV-to-Revenue is ranked lower than
73% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. EW: 6.84 )
Ranked among companies with meaningful EV-to-Revenue only.
EW' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.2  Med: 4.8 Max: 9.2
Current: 6.84
2.2
9.2
PEG Ratio 1.38
EW's PEG Ratio is ranked higher than
69% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. EW: 1.38 )
Ranked among companies with meaningful PEG Ratio only.
EW' s PEG Ratio Range Over the Past 10 Years
Min: 0.45  Med: 1.44 Max: 3.48
Current: 1.38
0.45
3.48
Shiller PE Ratio 57.91
EW's Shiller PE Ratio is ranked lower than
63% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. EW: 57.91 )
Ranked among companies with meaningful Shiller PE Ratio only.
EW' s Shiller PE Ratio Range Over the Past 10 Years
Min: 34.67  Med: 61.64 Max: 124.24
Current: 57.91
34.67
124.24
Current Ratio 3.49
EW's Current Ratio is ranked higher than
72% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. EW: 3.49 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.74 Max: 5.56
Current: 3.49
0.89
5.56
Quick Ratio 2.76
EW's Quick Ratio is ranked higher than
69% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. EW: 2.76 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.15 Max: 4.83
Current: 2.76
0.49
4.83
Days Inventory 193.28
EW's Days Inventory is ranked lower than
65% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. EW: 193.28 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 170.89 Max: 208.39
Current: 193.28
132.4
208.39
Days Sales Outstanding 52.31
EW's Days Sales Outstanding is ranked higher than
68% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. EW: 52.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 52.31
38.74
69.95
Days Payable 48.51
EW's Days Payable is ranked lower than
63% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. EW: 48.51 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.96  Med: 45.59 Max: 63.34
Current: 48.51
33.96
63.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.10
EW's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. EW: 1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EW' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0.5 Max: 2.2
Current: 1.1
-1.2
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 95.45
EW's Price-to-Net-Current-Asset-Value is ranked lower than
100% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. EW: 95.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EW' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.47  Med: 17.59 Max: 568
Current: 95.45
10.47
568
Price-to-Tangible-Book 13.03
EW's Price-to-Tangible-Book is ranked lower than
85% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. EW: 13.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EW' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.58  Med: 10.04 Max: 199.7
Current: 13.03
5.58
199.7
Price-to-Intrinsic-Value-Projected-FCF 2.34
EW's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
55% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. EW: 2.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EW' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.35  Med: 2.04 Max: 3.62
Current: 2.34
1.35
3.62
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.11
EW's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. EW: 1.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
EW' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.43  Med: 1.21 Max: 4.55
Current: 1.11
0.43
4.55
Price-to-Median-PS-Value 1.42
EW's Price-to-Median-PS-Value is ranked lower than
75% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. EW: 1.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EW' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.63 Max: 1.83
Current: 1.42
0.2
1.83
Price-to-Peter-Lynch-Fair-Value 2.00
EW's Price-to-Peter-Lynch-Fair-Value is ranked higher than
55% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. EW: 2.00 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EW' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.5 Max: 3.27
Current: 2
0.59
3.27
Price-to-Graham-Number 4.29
EW's Price-to-Graham-Number is ranked lower than
76% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. EW: 4.29 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EW' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.81  Med: 3.58 Max: 29.59
Current: 4.29
1.81
29.59
Earnings Yield (Greenblatt) % 4.07
EW's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. EW: 4.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EW' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 4.5 Max: 14.7
Current: 4.07
2.5
14.7
Forward Rate of Return (Yacktman) % 18.17
EW's Forward Rate of Return (Yacktman) % is ranked higher than
79% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. EW: 18.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EW' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 15.1  Med: 22.65 Max: 37.5
Current: 18.17
15.1
37.5

More Statistics

Revenue (TTM) (Mil) $3,314.50
EPS (TTM) $ 3.43
Beta0.65
Short Percentage of Float1.33%
52-Week Range $81.12 - 121.45
Shares Outstanding (Mil)211.62

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,390 3,723 4,016
EPS ($) 3.66 4.22 4.73
EPS without NRI ($) 3.66 4.22 4.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.69%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}